Search

Displaying results 2501 - 2510 of 7186 in total
  1. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    [A259591,A259542] By antagonizing NK3 receptors, neuronal signalling can be dampened to reduce VMS. … available for menopausal women, safety and tolerability concerns, such as an increased risk of stroke and venous thromboembolism or hormone-dependent cancer like breast cancer, can prevent some women from

  2. Drug

    Corynebacterium diphtheriae

    go.drugbank.com/drugs/DB09877
    ApprovedInvestigational

    *Corynebacterium diphtheriae* toxin is extracted from the pathogenic actinobacterium *C. diphtheriae* that causes diphtheria. … The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children.

    Mixtures: Td-pur für Erwachsene und Heranwachsende
  3. Drug

    Methotrexate

    go.drugbank.com/drugs/DB00563
    ApprovedInvestigational

    [A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma … [A180322] This inhibition leads to suppression of inflammation as well as prevention of cell division.

    Synonyms: 4-amino-N(10)-methylpteroylglutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acidProducts: TEXATE-T
  4. Drug

    Perboric acid

    go.drugbank.com/drugs/DB13235
    Approved

    [F66] Perboric acid in the form of sodium perborate is approved by Health Canada since 2004 to be used as a disinfectant of medical instruments. … Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate.

  5. Drug

    Poliovirus type 1 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10795
    ApprovedInvestigational

    The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. … type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by

    Mixtures: Td Polio Adsorbed, PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  6. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    The vaccine contains purified and inactivated poliovirus type 3 that were grown from a continuous line of monkey kidney cells. … type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by

    Mixtures: Td Polio Adsorbed, PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET
  7. Drug

    Motixafortide

    go.drugbank.com/drugs/DB14939
    ApprovedInvestigational

    [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation.

  8. Drug

    Metolazone

    go.drugbank.com/drugs/DB00524
    ApprovedInvestigational

    A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.

    Synonyms: 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone, 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide
  9. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.

    Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)
  10. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.